148 related articles for article (PubMed ID: 37957455)
1. Primary membranous nephropathy in the Italian region of Emilia Romagna: results of a multicenter study with extended follow-up.
Albertazzi V; Fontana F; Giberti S; Aiello V; Battistoni S; Catapano F; Graziani R; Cimino S; Scichilone L; Forcellini S; De Fabritiis M; Sara S; Delsante M; Fiaccadori E; Mosconi G; Storari A; Mandreoli M; Bonucchi D; Buscaroli A; Mancini E; Rigotti A; La Manna G; Gregorini M; Donati G; Cappelli G; Scarpioni R;
J Nephrol; 2024 Mar; 37(2):471-482. PubMed ID: 37957455
[TBL] [Abstract][Full Text] [Related]
2. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
[TBL] [Abstract][Full Text] [Related]
3. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
[TBL] [Abstract][Full Text] [Related]
4. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
5. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
Front Immunol; 2021; 12():738788. PubMed ID: 34721403
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
Lu W; Gong S; Li J; Luo H; Wang Y
Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
[TBL] [Abstract][Full Text] [Related]
7. Renal outcomes of idiopathic and atypical membranous nephropathy in adult Chinese patients: a single center retrospective cohort study.
Jiang Z; Cai M; Dong B; Yan Y; Wang Y; Li X; Shao C; Zuo L
BMC Nephrol; 2021 Apr; 22(1):148. PubMed ID: 33888083
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
[TBL] [Abstract][Full Text] [Related]
9. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
[TBL] [Abstract][Full Text] [Related]
10. A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up.
Zhou XJ; Zhou FD; Wang SX; Zhao MH
Medicine (Baltimore); 2018 Jun; 97(25):e11184. PubMed ID: 29924035
[TBL] [Abstract][Full Text] [Related]
11. Membranous Nephropathy: It Is Time to Go Back to the Future.
Sabiu G; Podestà MA
Nephron; 2021; 145(6):721-727. PubMed ID: 34225270
[TBL] [Abstract][Full Text] [Related]
12. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952
[TBL] [Abstract][Full Text] [Related]
15. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
Yan P; Fang X; Ke B
Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
[TBL] [Abstract][Full Text] [Related]
16. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
[TBL] [Abstract][Full Text] [Related]
17. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in idiopathic membranous nephropathy.
Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis.
Zhang J; Bian L; Ma FZ; Jia Y; Lin P
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):8021-8029. PubMed ID: 30536351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]